Among @ genotype @b-infected chronic hepatitis C patients recruited , @ eligible patients were allocated randomly to two study arms ; they received @ weeks of telaprevir/peg-IFN/RBV , followed by @ weeks of peg-IFN/RBV with or without @ weeks of fluvastatin ( fluvastatin group and control group , respectively ) .